{
    "nctId": "NCT00326820",
    "briefTitle": "Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer",
    "officialTitle": "Zoledronate Versus Ibandronate Comparative Evaluation: A Randomized Phase III, Open-Label, Multicenter, Parallel Group Clinical Trial to Evaluate and Compare the Efficacy, Safety Profile and Tolerability of Oral Ibandronate Versus Intravenous Zoledronate in the Treatment of Breast Cancer Patients With Bone Metastases",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 1404,
    "primaryOutcomeMeasure": "Frequency and timing of skeletal-related events (SREs)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically proven breast cancer\n\n  * Metastatic disease\n  * Previous relapsed disease in sites other than bone allowed\n* Newly diagnosed multiple bone metastases within the past 3 months, meeting all of the following criteria:\n\n  * Painful or asymptomatic\n  * Lytic, mixed, or purely sclerotic type\n  * Radiological diagnosis\n  * IV bisphosphonate therapy indicated\n* No CNS metastases\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status 0-2\n* Male or female\n* Menopausal status not specified\n* No known active peptic ulcer\n* Not pregnant or nursing\n* Fertile patients must use effective contraception\n* No active dental problems, including infection of the teeth or jawbone (maxilla or mandible) or dental or fixture trauma\n* No prior or current diagnosis of osteonecrosis of the jaw, exposed bone in the mouth, or slow healing after dental procedures\n* Creatinine clearance \u2265 30 mL/min\n* Bilirubin \u2264 1.5 x upper limit of normal (ULN)\n* AST and ALT \u2264 1.5 times ULN\n* No history of bisphosphonate hypersensitivity\n* Able to comply with instructions relating to oral study medications\n* Able to take oral study medications\n* No psychiatric illness or other condition that would preclude giving informed consent\n\nPRIOR CONCURRENT THERAPY:\n\n* At least 6 months since prior bisphosphonate therapy\n* At least 6 weeks since prior and no concurrent dental or jaw surgery (e.g., extractions or implants)\n\n  * Concurrent unplanned dental extractions allowed provided study medication is discontinued for 8 weeks before and after the surgery\n* Concurrent chemotherapy and/or hormone therapy for metastatic disease allowed\n* No concurrent medications that affect bone metabolism (e.g., calcitonin or other nontrial bisphosphonates)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}